Sugi Predict

Sugi Predict / Compounds / SCHEMBL1868464

SCHEMBL1868464

SCHEMBL1868464

COC(=O)c1cc(Br)cc2[nH]ccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 8/20 0.52
▸ CHEK1 O14757 2/20 0.50
▸ PIM3 Q86V86 2/20 0.49
▸ PIM1 P11309 1/20 0.49
▸ CREBBP Q92793 1/20 0.46
▸ TTBK1 Q5TCY1 1/20 0.43
▸ TTBK2 Q6IQ55 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ TUBB4A P04350 1/20 0.40
▸ TUBB P07437 1/20 0.40
▸ TUBA3C P0DPH7 1/20 0.40
▸ TUBA1B P68363 1/20 0.40
▸ TUBA4A P68366 1/20 0.40
▸ TUBB4B P68371 1/20 0.40
▸ TUBB3 Q13509 1/20 0.40
▸ TUBB2A Q13885 1/20 0.40
▸ TUBB8 Q3ZCM7 1/20 0.40
▸ TUBA3E Q6PEY2 1/20 0.40
▸ TUBA1A Q71U36 1/20 0.40
▸ TUBA1C Q9BQE3 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2314520 0.83 NR4A2 (0.63) NR4A2CHEK1PIM3PIM1CREBBP
SCHEMBL6418376 0.83 NR4A2 (0.51) NR4A2CHEK1PIM3PIM1CREBBP
SCHEMBL2210582 0.81 NR4A2 (0.50) NR4A2CHEK1PIM3PIM1CREBBP
SCHEMBL20692462 0.81 NR4A2 (0.50) NR4A2CHEK1PIM3PIM1CREBBP
SCHEMBL31099333 0.81 NR4A2 (0.50) NR4A2CHEK1PIM3PIM1CREBBP
SCHEMBL2309361 0.81 NR4A2 (0.64) NR4A2CHEK1PIM3PIM1CREBBP
SCHEMBL12432932 0.81 NR4A2 (0.50) NR4A2CHEK1PIM3PIM1CREBBP
SCHEMBL20604730 0.81 NR4A2 (0.47) NR4A2CHEK1PIM3PIM1CREBBP
SCHEMBL16115819 0.80 DHODH (0.44) HTR6ALDH1A1
SCHEMBL6418381 0.80 AURKA (0.49) NR4A2CHEK1PIM3PIM1CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122055363-A Compounds and methods for modulating splicing 雷密克斯医疗公司 2026-05-15 — — CN disclosed
EP-4724438-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2026-04-15 — — EP disclosed
EP-3717487-B1 PYRIDINONE-BASED EPIGENETIC MODIFIERS AND USES THEREOF UNIV ILLINOIS (US) 2025-10-08 — — EP disclosed
EP-4620531-A2 BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF Revolution Medicines, Inc. (US) 2025-09-24 — — EP disclosed
US-20250179017-A1 CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) 2025-06-05 — — US disclosed
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof Revolution Medicines, Inc. (US) 2025-03-25 — — US disclosed
US-12258314-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2025-03-25 — — US disclosed
CN-119487006-A Amide compounds as PGE2 receptor antagonists 广东新契生物医药科技有限公司 2025-02-18 — — CN disclosed
US-20250049812-A1 Compounds that Inhibit Necroptosis and Their Preparation Methods SHANGHAI INST ORGANIC CHEMISTRY CAS (CN) 2025-02-13 — — US disclosed
EP-4482824-A1 CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS Guangdong Newopp Biopharmaceuticals Co., Ltd. (CN) 2025-01-01 — — EP disclosed
US-20100240702-A1 Benzimidazolone Chymase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 — — US disclosed
WO-2010100475-A1 HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS ASTRAZENECA AB (SE) 2010-09-10 — — WO disclosed
WO-2010093849-A2 PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS AMGEN INC. (US) 2010-08-19 — — WO disclosed
EP-2152674-A1 BENZIMIDAZOLONE CHYMASE INHIBITORS Boehringer Ingelheim International GmbH (DE) 2010-02-17 — — EP disclosed
WO-2008147697-A1 BENZIMIDAZOLONE CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-12-04 — — WO disclosed
WO-2008147697-A1 BENZIMIDAZOLONE CHYMASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-12-04 — — WO disclosed
EP-0734386-B1 PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES ABBOTT LAB (US) 2002-02-06 — — EP disclosed
EP-0734386-A1 PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES Abbott Laboratories (US) 1996-10-02 — — EP disclosed
US-5486525-A ANTIINFLAMMATORY AGENTS ABBOTT LABORATORIES (US) 1996-01-23 — — US disclosed
WO-1995016687-A1 PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES ABBOTT LABORATORIES (US) 1995-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258314-B2 EBNA1 inhibitors and their method of use EBNA1BP2, MLLT1, PML NR4A2 1577/4885CHEK1 2346/4885PIM3 3111/4885
US-20250179017-A1 CARBOXAMIDE COMPOUNDS AS PGE2 RECEPTOR ANTAGONISTS PTGER1, PTGER2, CNR2 NR4A2 942/4885CHEK1 3870/4885PIM3 3521/4885
US-20100240702-A1 Benzimidazolone Chymase Inhibitors CMA1, SERPINB1, CPA3 NR4A2 4239/4885CHEK1 518/4885PIM3 851/4885
US-20250049812-A1 Compounds that Inhibit Necroptosis and Their Preparation Methods RIPK1, RIPK3, RIPK4 NR4A2 1911/4885CHEK1 405/4885PIM3 1345/4885
US-12258366-B2 Bicyclic heteroaryl compounds and uses thereof SOST, SOS1, SOS2 NR4A2 1681/4885CHEK1 3183/4885PIM3 3353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.